Three Part D changes take effect January 1, and the 2027 premium outlook depends heavily on how many enrollees switch plans during Open Enrollment. CMS ended the Part D Premium Stabilization Demonstration after the 2026 plan year, the annual out-of-pocket cap rises from $2,100 to $2,400, and negotiated prices for 15 more drugs begin. CMS projects the average stand-alone drug plan premium at $36, up less than $1 from $35.09 and based on September 2026 enrollment, and KFF projects $51, up $17 from $34, based on June 2026 enrollment with every current enrollee assumed to stay in the same plan. Medicare Open Enrollment closes December 7, so the range between those two figures is being settled in real decisions right now.
What the demonstration did and why CMS ended the program
CMS launched the demonstration in 2025 after the Inflation Reduction Act redesigned the Part D benefit and left stand-alone plan premiums uncertain. Participating plans received a fixed-dollar reduction in the base beneficiary premium, and an annual dollar limit held down how much a plan’s premium rose from one year to the next. CMS announced on July 28 the program would end after 2026, saying sponsors now have enough experience with the redesigned benefit to support their bids. The 2027 national average monthly bid amount is $296.05, up 24 percent, and the base beneficiary premium is $41.33, up 6 percent from $38.99 and the maximum increase the law allows.
Ending the program removes the premium increase limit, which stood at $50 a month in 2026. Under the limit, only 38,000 non-low-income stand-alone enrollees faced an increase above $50 last year.
How switching shapes the premium range
The two estimates use different enrollment snapshots, and KFF’s $51 estimate assumes no one changes plans, and KFF expects the actual average to land lower because switching during Open Enrollment pulls the figure down. The plan-level numbers show how much rides on the choice. If non-low-income stand-alone enrollees make no changes, 76 percent, or 10.4 million of 13.6 million, will pay more in 2027, compared with 56 percent in 2026, and 2.4 million will face increases above $50 a month. No zero-premium stand-alone plans are available to those enrollees in 2027, which affects about 4 million people who paid nothing in 2026.
The spread across national plans is wide. In KFF’s plan-by-plan review, Wellcare Value Script holds at $5.30 a month in 45 states, with enrollees in 29 states seeing decreases of up to $17.50, while AARP Medicare Rx Preferred rises by $50 or more for enrollees who stay in every state and above $75 in 37 states. A national average of $36 sits on top of those two experiences and describes neither, which is why plan sponsors will learn more from switching behavior and renewal notice response in January than from the average itself.
Fewer stand-alone plans and a wider gap with MA drug coverage
The average beneficiary will see 9 stand-alone plans in 2027, down from 11 in 2026 and the fourth straight annual decline, and the total number of stand-alone plans falls from 360 to 316, offered by 15 parent organizations rather than 17. Health Care Service Corporation is withdrawing HealthSpring Extra Rx from 22 regions and CVS Health is withdrawing SilverScript Choice from 13. Medicare Advantage drug plans sit on the other side of a growing divide, with an average Part D premium of $9 in KFF’s estimate compared with $51 for stand-alone plans, because MA plans use rebate dollars to lower drug premiums and stand-alone plans have no equivalent. About 56 percent of Part D enrollees were in MA drug plans in 2026, and most of them are unaffected by stand-alone premium changes, so the pressure lands on members in Original Medicare and on the MA organizations competing to enroll them.
Cost sharing and negotiated prices on January 1
The standard deductible rises from $615 to $700, and the out-of-pocket threshold rises 14 percent, from $2,100 to $2,400. Across plans, 99.8 percent of stand-alone enrollees and 85 percent of MA drug plan enrollees will be in a plan with a deductible, up from 96 percent and 80 percent in 2026. Negotiated prices for 15 more drugs take effect the same day, including Ozempic, Wegovy, Trelegy Ellipta and Xtandi, and CMS estimates $685 million in out-of-pocket savings for enrollees in 2027. Those join the 10 drugs whose negotiated prices began January 1, 2026, bringing the total to 25. Our November 13 article covers the final negotiation rule and what the program means for formularies and bids starting with 2029 prices.
What the January data will show
Open Enrollment closes December 7, and January enrollment data will show which version of the premium story holds. Switching rates among the 10.4 million enrollees facing increases will decide whether the average lands nearer $36 or $51, and the first claims under the $2,400 cap and the new negotiated prices will show how bids built a year ago performed.
RISE National 2027 brings Medicare Advantage leaders across operations, marketing, sales and risk adjustment together March 16 to 18 at Caesars Forum in Las Vegas, with new Sales & Strategic Growth and Marketing & Member Acquisition tracks on how plans compete for members after Open Enrollment.